3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
39
Squamous Cell Carcinoma of Head and Neck
20
Lung Neoplasms
20
Oropharyngeal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Urinary Bladder Neoplasms
7
Uterine Cervical Neoplasms
6
Endometrial Neoplasms
6
Carcinoma
6
Pancreatic Neoplasms
5
Mouth Neoplasms
5
Colorectal Neoplasms
5
Cholangiocarcinoma
5
Biliary Tract Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Nasopharyngeal Carcinoma
4
Laryngeal Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Squamous Cell
4
Mesothelioma, Malignant
3
Lymphoid Interstitial Pneumonia
3
Hypopharyngeal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Tongue Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Interventions
tivozanib
2
durvalumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Cisplatin
2
olaparib
1
atezolizumab
1
Stents
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Cisplatin
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts
NCT06274879
2026-05-26
Ablatio
Insel Gruppe AG, University Hospital Bern
Phase 2
Recruiting
36 enrolled